Last mentioned: Mar 19, 2026
Healthy China 2030 Deadline
Target date for achieving major healthcare and biotech self-sufficiency milestones.
Implementation Phase
Expected rollout of specific subsidies and domestic-first procurement policies.
Official Launch
President Xi Jinping unveils the 15th FYP at the National People's Congress.
15th FYP Announcement
China officially prioritizes tech self-reliance as the central pillar of the 2026-2030 plan.
15th FYP Drafting
Central Committee reviews the initial draft of the 2026-2030 strategic plan.
Geopolitical Escalation
U.S. introduces Biosecure Act, targeting major Chinese biotech entities.
14th FYP Implementation
Focus on 'Dual Circulation' and initial biotech innovation pivot.
14th Five-Year Plan
Initial focus on 'Dual Circulation' and building basic biotech infrastructure.
President Xi Jinping’s 15th Five-Year Plan (2026-2030) positions biotechnology as a cornerstone of "New Quality Productive Forces," prioritizing domestic innovation and supply chain self-sufficiency. This strategic shift aims to decouple China’s life sciences sector from Western dependencies while accelerating the commercialization of cell and gene therapies.
China has officially signaled a shift toward total technological self-reliance in its 15th Five-Year Plan, prioritizing the domestic life sciences and pharmaceutical sectors. This strategic pivot aims to insulate China’s healthcare infrastructure from global supply chain volatility and geopolitical pressures while fostering a homegrown innovation ecosystem.
This page surfaces every story mentioning BeiGene across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where BeiGene was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |